News | Page 9 of 10 | 53Biologics

March 3, 2022 Patricia De La Madrid Comments: 0

Which Are Better? Biologics or Small Molecule Drugs?

So to decide which is the best option in medicine and biopharma between biologics or small molecule drugs, we have to consider many factors. But let´s start from the beginning. What Is a Small Molecule Drug? Small molecule drugs are typically derived from natural compounds produced by plants, fungi and bacteria or are designed to imitate them. These drugs use biochemical processes to prevent or treat diseases. They are highly effective as allosteric modulators and enzyme inhibitors, and are...

February 23, 2022 Patricia De La Madrid Comments: 0

Biologics CDMO: Why You Need One

The rapidly growing market for biologics has made contract biologics development and production corporations (CDMO) more essential. The complexity inherent in the development of biologics and their mass production for sale makes it impossible for biopharmaceutical and pharmaceutical companies to perform the process in-house. What Is a Biologics CDMO Company? A contract biologics development and manufacturing company (CDMO) provides medical biologics development and manufacturing services for p...

February 16, 2022 Patricia De La Madrid Comments: 0

Accelerating Biologics Manufacturing

In today’s pharmaceutical and biotechnology industry, the focus is on reducing development time and obtaining faster approval for high-quality therapies. However, biologics present unique and time-consuming challenges, such as cell line and analytical development, biological instability, scale-up and limited capacity, which can negatively impact time to market and financial results. Here are 5 steps to create a successful strategy that will help accelerate the time to a robust and reliable...

200GMP-compliant microbial fermentation bioreactor/53Biologics

October 1, 2021 Patricia De La Madrid Comments: 0

Empowering Therapies for Rare Diseases: OLIGOFASTX project

In a world where medical solutions are constantly evolving, OLIGOFASTX emerges as a beacon of hope for those battling rare diseases with no existing treatments. This groundbreaking project spearheaded by our CDMO aims to revolutionize therapy development, paving the way for novel oligonucleotide-based treatments like antimiRNAs, siRNAs, and aptamers. With OLIGOFASTX, we’re not just creating therapies – we’re shaping a future where patients have access to life-changing treatments th...

September 13, 2021 Patricia De La Madrid Comments: 0

Conquering Delta: Our mRNA Vaccine Mission

Amidst the evolving landscape of the COVID-19 pandemic, our company has embarked on an essential project named STABVAC4COV. This groundbreaking initiative aims to develop mRNA-based vaccines tailored specifically to combat the highly transmissible Delta variant of SARS-CoV-2. With the main objective of creating an effective preventive measure against the Delta variant, our dedication to innovation and public health shines brighter than ever. Join us on this critical journey towards a safer, heal...

April 15, 2021 Patricia De La Madrid Comments: 0

Why is Pichia Pastoris a good alternative for the production of recombinant proteins?

Pichia pastoris is a methylotrophic yeast belonging to the class Ascomycetes. Found in the 1960s, its main characteristic is to use methanol as a carbon and energy source. After years of study, P. pastoris has become a model organism for genetic study, being important in the field of biological and biotechnological research. Pichia pastoris is a yeast currently widely used as an expression system for the production of recombinant proteins, both for basic research and industrial purposes,...

March 17, 2021 Patricia De La Madrid Comments: 0

What is the best known living being in the scientific field?

The best known organism in science is certainly a bacterium that lives in the human intestine and in 53Biologics we are experts in this bacteria. Invisible to the naked eye, Escherichia coli is largely responsible for the knowledge of some of the fundamentals of modern biology that have been recognized by several Nobel prizes. These are the processes of bacterial genetic recombination, RNA transcription, DNA replication and gene regulation. In addition, in recent decades this bacterium has...

February 11, 2021 Patricia De La Madrid Comments: 0

Vaccines need a supply chain

The long-awaited immunization vaccines for SARS-CoV2 have arrived, and for us all to get back to “normal” again, rapid application and sustained large-scale production are required. On them depends to a large extent to achieve recovery and reduce the economic and human impact that Covid-19 is causing. Generally, vaccines work by exposing to the immune system a virus or part of it, which has been previously weakened or attenuated. When the vaccinated immune system subsequently encounters...

March 1, 2020 Patricia De La Madrid Comments: 0

Production of Certolizumab in C1

We are thrilled to announce a groundbreaking project that has the potential to revolutionize the treatment landscape for inflammatory diseases. Thanks to the collaboration between our company and the support of CDTI and FEDER funds, we are embarking on the development of a biosimilar for Certolizumab-C1. This biosimilar, produced in the filamentous fungus Myceliophthora thermophila C1, holds promise in offering cost-effective and accessible treatment options to patients in need. With this projec...

February 21, 2020 Patricia De La Madrid Comments: 0

Empowering Growth: New GMP Facility Unveiled!

We are thrilled to announce the launch of our latest endeavor: the construction and procurement of a state-of-the-art GMP certified facility for cell bank generation services. Supported by the European Regional Development Fund (ERDF) of the European Union and the Junta de Castilla y León, through the Instituto para la Competitividad Empresarial de Castilla y León (ICE), this project signifies a monumental step forward in our mission to enhance competitiveness and innovation within the biophar...